9 Meters Biopharma Inc. (NASDAQ:NMTR) does about 5.56M shares in volume on a normal day but saw 7687319 shares change hands in Friday trading. The company now has a market cap of 98.86M USD and an enterprise value of about $89.85M. Its current market price is $0.66, marking a decrease of -7.30% compared to the previous close of $0.71. The 52 week high reached by this stock is $1.29 whilst the lowest price level in 52 weeks is $0.37. The script in recent trading has seen the stock touch a high of $0.7059 and a low of $0.65.

9 Meters Biopharma Inc. (NMTR) has a 20-day trading average at $0.5489 and the current price is -48.88% off the 52-week high compared with 78.17% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.5615. If we look at the stock’s price movements over the week, volatility stands at 22.61%, which decreases to 12.50% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 57.25 to suggest the stock is neutral.

2 analysts observing the 9 Meters Biopharma Inc. (NMTR) stock have set the 12-month price targets for the company’s shares at between $5.00 and $5.00. The median price target is 86.8% away from the current levels at $5.00.

FactSet Research has provided data showing that 2 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 2 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Moderate Buy the stock.

The current price level is 21.74%, 17.77%, and 7.04% away from its SMA20, SMA50, and SMA200 respectively, with the NMTR price moving below the 50-day SMA on August 21. 9 Meters Biopharma Inc. (NMTR) stock is up 15.85% over the week and 22.59% over the past month. Its price is 18.36% year-to-date and -24.67% over the past year.

The stock last released its quarterly earnings report for quarter ended 9/29/2019, with the company’s earnings per share (EPS) of -$0.26 below consensus estimates by -$0.12.

Its 12-month price target is $5.00. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $5.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $5.00.

Outstanding shares total 138.93M with insiders holding 10.24% of the shares and institutional holders owning 2.73% of the company’s common stock. The beta has a value of -4.88. Price to book ratio is 16.48.

According to a U.S. Securities and Exchange Commission filing, Vanguard Total Stock Market Index has reduced its position in 9 Meters Biopharma Inc. (NMTR) to 514,938 shares, mirroring a recent drop by 0.00%. Vanguard Total Stock Market Index dumped 0.0 shares of 9 Meters Biopharma Inc. common stock bringing its total worth to about $0.25 million at the end of recent close, SEC documents show. Vanguard Total Stock Market Index isn’t the only investment manager who changed stakes and is followed by Vanguard Extended Market Index Fu, which sold off 0.0 shares to end up with 200,245 shares worth $95317.0. Fidelity Extended Market Index Fu cut their holdings by 0.00% in the company over the course of the most recent quarter. It now holds a 0.04% position in 9 Meters Biopharma Inc. thanks to 53980.0 shares amounting to $25694.0.